Technical Analysis for SNSS - Sunesis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 0.8443 -8.23% -0.08
SNSS closed down 8.23 percent on Monday, March 18, 2019, on 1.36 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical SNSS trend table...

Date Alert Name Type % Chg
Mar 18 Bearish Engulfing Bearish 0.00%
Mar 18 Wide Range Bar Range Expansion 0.00%
Mar 18 Upper Bollinger Band Walk Strength 0.00%
Mar 18 Weak + Overbought Other 0.00%
Mar 18 Outside Day Range Expansion 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Weak, Overbought and Reversal Signs Reversal 0.00%
Mar 18 Overbought Stochastic Strength 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 Upper Bollinger Band Walk Strength -8.23%

Older signals for SNSS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Biopharmaceutical Drugs Chemical Compounds Organic Compounds Acute Myeloid Leukemia Myelodysplastic Syndrome Orphan Drugs Treatment Of Acute Myeloid Leukemia Biogen Lactams High Risk Myelodysplastic Syndrome
Is SNSS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.56
52 Week Low 0.2
Average Volume 768,353
200-Day Moving Average 1.4491
50-Day Moving Average 0.5732
20-Day Moving Average 0.6203
10-Day Moving Average 0.7045
Average True Range 0.0839
ADX 32.67
+DI 37.3232
-DI 4.4812
Chandelier Exit (Long, 3 ATRs ) 0.7483
Chandelier Exit (Short, 3 ATRs ) 0.7517
Upper Bollinger Band 0.8683
Lower Bollinger Band 0.3723
Percent B (%b) 0.95
BandWidth 79.961309
MACD Line 0.0767
MACD Signal Line 0.0415
MACD Histogram 0.0352
Fundamentals Value
Market Cap 19.85 Million
Num Shares 23.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 24.54
Price-to-Book 0.00
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.16
Resistance 3 (R3) 1.18 1.09 1.11
Resistance 2 (R2) 1.09 1.01 1.08 1.09
Resistance 1 (R1) 0.97 0.96 0.92 0.95 1.07
Pivot Point 0.88 0.88 0.86 0.87 0.88
Support 1 (S1) 0.76 0.80 0.71 0.74 0.62
Support 2 (S2) 0.67 0.75 0.66 0.60
Support 3 (S3) 0.55 0.67 0.58
Support 4 (S4) 0.53